Presentation CDM 2017 Can Heart Disease be Eventually Abolished? The PCSK9 Revolution Presenter: Robert A. Vogel October 06, 2017 REGISTER for free or LOG IN to view this content Clinical Cardiology Clinical Pharma Coronary CAD Pharma Presentation CDM 2017 Up Next Presentation AHA 2017 Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial Presenter: Akihiko Nogami November 13, 2017 More slides + Presentation AHA 2017 Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial Presenter: Steven Weisbord November 13, 2017 Presentation AHA 2017 Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Presenter: Louise Bowman November 14, 2017 We Recommend
Presentation AHA 2017 Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial Presenter: Akihiko Nogami November 13, 2017
Presentation AHA 2017 Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial Presenter: Steven Weisbord November 13, 2017
Presentation AHA 2017 Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Presenter: Louise Bowman November 14, 2017